Dexetimide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329016

CAS#: 21888-98-2 (free base)

Description: Dexetimide, also known as Serenone and R-16470, is a muscarinic cholinergic antagonist that has been used to treat neuroleptic-induced parkinsonism.

Chemical Structure

img
Dexetimide
CAS# 21888-98-2 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 329016
Name: Dexetimide
CAS#: 21888-98-2 (free base)
Chemical Formula: C23H26N2O2
Exact Mass: 362.20
Molecular Weight: 362.473
Elemental Analysis: C, 76.21; H, 7.23; N, 7.73; O, 8.83

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 21888-96-0 (HCl)   21888-98-2 (free base)  

Synonym: Dexetimide; R 16470; R-16470; R16470; Serenone; Tremblex

IUPAC/Chemical Name: (R)-1'-benzyl-3-phenyl-[3,4'-bipiperidine]-2,6-dione

InChi Key: LQQIVYSCPWCSSD-QHCPKHFHSA-N

InChi Code: InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m0/s1

SMILES Code: O=C([C@@](C1=CC=CC=C1)(C2CCN(CC3=CC=CC=C3)CC2)CC4)NC4=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 362.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bakker G, Vingerhoets WA, van Wieringen JP, de Bruin K, Eersels J, de Jong J, Chahid Y, Rutten BP, DuBois S, Watson M, Mogg AJ, Xiao H, Crabtree M, Collier DA, Felder CC, Barth VN, Broad LM, Bloemen OJ, van Amelsvoort TA, Booij J. 123I-iododexetimide preferentially binds to the muscarinic receptor subtype M1 in vivo. J Nucl Med. 2015 Feb;56(2):317-22. doi: 10.2967/jnumed.114.147488. Epub 2015 Jan 15. PubMed PMID: 25593117.

2: Knol RJ, de Bruin K, Opmeer B, Voorn P, Jonker AJ, van Eck-Smit BL, Booij J. Decreased ipsilateral [¹²³I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats. Nucl Med Biol. 2014 Jan;41(1):90-5. doi: 10.1016/j.nucmedbio.2013.10.003. Epub 2013 Oct 18. PubMed PMID: 24267055.

3: Jain KK, Hauptman PJ, Spertus JA, Kennedy KF, Bateman TM, Jacobson AF, Stolker JM. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. J Card Fail. 2014 Aug;20(8):577-83. doi: 10.1016/j.cardfail.2014.06.001. Epub 2014 Jun 18. PubMed PMID: 24951931.

4: Lüllmann H, Schmaus H, Staemmler C, Ziegler A. Comparison of atropine and dexetimide in treatment of intoxications by selected organophosphates. Acta Pharmacol Toxicol (Copenh). 1982 Mar;50(3):230-7. PubMed PMID: 7046345.

5: Sánchez-Roa PM, Wagner HN Jr, Villemagne VL, London ED, Lever JR. Effects of extracellular acetylcholine on muscarinic receptor binding assessed by [125I]dexetimide and a simple probe. Eur J Pharmacol. 1998 Oct 9;358(3):207-11. PubMed PMID: 9822886.

6: Zwanikken GJ, Oei TT, Kimya S, Amery W. Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study. Acta Psychiatr Belg. 1976 May;76(3):467-9. PubMed PMID: 1020682.

7: Uno Y, Matsumura K, Scheffel U, Wilson AA, Dannals RF, Wagner HN Jr. Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors. Eur J Nucl Med. 1991;18(7):447-52. PubMed PMID: 1915471.

8: DeHaven-Hudkins DL, Hudkins RL. Binding of dexetimide and levetimide to [3H](+)pentazocine- and [3H]1,3-di(2-tolyl)guanidine-defined sigma recognition sites. Life Sci. 1991;49(18):PL135-9. PubMed PMID: 1656155.

9: Deze J, Völler GW. Treatment of Parkinsonian syndrome with dexetimide. Acta Psychiatr Belg. 1979 Nov-Dec;79(6):704-11. PubMed PMID: 554448.

10: Wauquier A, Niemegeers CJ, Lal H. Differential antagonism by the antichlolinergic dexetimide of inhibitory effects of haloperidol and fentanyl on brain self-stimulation. Psychopharmacologia. 1975;41(3):229-35. PubMed PMID: 1153612.

11: Chen Y. [A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects]. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Aug;24(4):197-9, 251. Chinese. PubMed PMID: 1683277.

12: Dannals RF, Långström B, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimide. Int J Rad Appl Instrum A. 1988;39(4):291-5. PubMed PMID: 2838435.

13: Lüllmann H, Reil GH, Timmermans PB, Ziegler A. [The influence of the beat frequency on the time course of drug binding and pharmacological action of dexetimide in atrial muscle (author's transl)]. Arch Pharm (Weinheim). 1980 Aug;313(8):657-67. German. PubMed PMID: 7416924.

14: Boundy KL, Barnden LR, Katsifis AG, Rowe CC. Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer's disease. J Clin Neurosci. 2005 May;12(4):421-5. PubMed PMID: 15925773.

15: Skopová J, Faltus F, Filip V, Jirák R, Karen P, Posmurová M, Dobiásová A. [Fluspirilene in schizophrenia maintenance therapy and its interaction with dexetimide]. Cesk Psychiatr. 1985 Dec;81(6):414-9. Czech. PubMed PMID: 3912068.